{"url_path":"/sec/avxl/8-k/2026-07-20/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 ****Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1314052/0001731122-26-000957-index.html","accession_number":"0001731122-26-000957","cik":"0001314052","ticker":"AVXL","issuer_name":"ANAVEX LIFE SCIENCES CORP.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1314052/0001731122-26-000957-index.html","primary_entity_key":"0001314052","primary_entity_name":"ANAVEX LIFE SCIENCES CORP."},"word_count":260,"has_tables":true,"body_markdown":"**Item 8.01.****Other Events.**\n\n** **\n\nOn July 20, 2026, Anavex Life Sciences Corp. (the “Company”)\ntimely submitted its plan (the “Compliance Plan”) to the Listing Qualifications Department (the “Nasdaq Staff”)\nof The Nasdaq Stock Market LLC to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file\nall required periodic financial reports with the Securities and Exchange Commission (“Rule 5250(c)(1)”). As previously disclosed,\non May 20, 2026, the Company received a deficiency notification letter (the “Notice”) from the Nasdaq Staff indicating that,\nas a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31,\n2026, it is not in compliance with Rule 5250(c)(1).\n\n \n\nThe Notice has no immediate effect on the listing of the Company’s\ncommon stock, which continues to trade on The Nasdaq Global Select Market under the symbol “AVXL”.\n\n \n\nThe Compliance Plan is currently under review by the Nasdaq Staff. If the\nCompliance Plan is accepted by the Nasdaq Staff, the Nasdaq Staff may grant an extension for the Company to regain compliance. If the\nCompliance Plan is not accepted by the Nasdaq Staff, the Company will have an opportunity to request a hearing on the Nasdaq Staff’s\ndetermination before an independent Hearings Panel.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the\nregistrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n \n**ANAVEX LIFE SCIENCES CORP.**\n\n \n \n \n \n\nDate:\nJuly 20, 2026\nBy:\n/s/ Sandra Boenisch\n\n \n \n \nSandra Boenisch, CPA, CGA\n\nPrincipal Financial Officer, Treasurer"}